Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations
Phase 3
- Conditions
- Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations
- Registration Number
- JPRN-C000000376
- Lead Sponsor
- EJ Gefitinib Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 320
Inclusion Criteria
Not provided
Exclusion Criteria
1.With lung fibrosis detectable in chest CT 2.With gefitinib resistant EGFR mutation (T790M) 3.With symptomatic brain metastasis 4.Previous radiotherapy to primary lung cancer 5.With severe co-morbidities 6.With active double cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method